# Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients

> **NCT04672564** · PHASE3 · TERMINATED · sponsor: **Shenyang Tonglian Group CO., Ltd** · enrollment: 93 (actual)

## Conditions studied

- Coronavirus Disease 2019

## Interventions

- **DRUG:** Carrimycin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04672564
- **Lead sponsor:** Shenyang Tonglian Group CO., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-30
- **Primary completion:** 2022-03-24
- **Final completion:** 2022-05-09
- **Target enrollment:** 93 (ACTUAL)
- **Why stopped:** sponsor strategy change
- **Last updated:** 2023-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04672564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04672564, "Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04672564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*